January 29, 2015 9:40 AM ET

Pharmaceuticals

Company Overview of Lantheus Medical Imaging, Inc.

Company Overview

Lantheus Medical Imaging, Inc. develops, manufactures, and distributes diagnostic medical imaging products. It offers imaging agents that assist in the diagnosis of heart, vascular, and other diseases using nuclear imaging, echocardiography, and magnetic resonance imaging (MRI) technologies. The company also has clinical and preclinical development pipeline of products that use positron emission tomography and MRI technologies. It principally offers Ablavar, a magnetic resonance angiography agent to evaluate aortoiliac disease in adult patients; DEFINITY Vial, a cardiac ultrasound contrast agent used for suboptimal echocardiograms; Cardiolite, a technetium-based radiopharmaceutical used in m...

Building 200-2

331 Treble Cove Road

North Billerica, MA 01862

United States

Founded in 1956

519 Employees

Phone:

978-671-8001

Fax:

978-671-8860

Key Executives for Lantheus Medical Imaging, Inc.

Chief Executive Officer
Age: 51
Chief Financial Officer
Age: 52
Vice President of Manufacturing and Operations
Age: 42
Vice President
Age: 53
Chief Medical Officer
Age: 64
Compensation as of Fiscal Year 2014.

Lantheus Medical Imaging, Inc. Key Developments

Lantheus Medical Imaging, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Lantheus Medical Imaging, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported revenues of $75,682,000 against $70,385,000 a year ago. Operating income was $11,540,000 against operating loss of $4,568,000 a year ago. Income before income taxes was $1,396,000 against loss before income taxes of $15,343,000 a year ago. Net income was $1,452,000 against net loss of $15,064,000 a year ago. Adjusted net income was $1,452,000 against adjusted net loss of $8,276,000 a year ago. EBITDA was $16,060,000 against $1,731,000 a year ago. Adjusted EBITDA was $19,057,000 against $11,908,000 a year ago. Net cash used in operating activities was $19,688,000 against $4,291,000 a year ago. Capital expenditures were $1,823,000 against $915,000 a year ago. For the nine months, the company reported revenues of $224,631,000 against $212,004,000 a year ago. Operating income was $30,009,000 against operating loss of $17,680,000 a year ago. Loss before income taxes was $1,843,000 against $49,109,000 a year ago. Net loss was $1,469,000 against $49,376,000 a year ago. Adjusted net loss was $1,469,000 against $42,588,000 a year ago. EBITDA was $43,061,000 against $2,079,000 a year ago. Adjusted EBITDA was $51,392,000 against $23,203,000 a year ago. Net cash used in operating activities was $15,448,000 against net cash used in operating activities of $11,822,000 a year ago. Capital expenditures were $5,303,000 against $3,711,000 a year ago.

Lantheus Medical Imaging, Inc., Q3 2014 Earnings Call, Nov 12, 2014

Lantheus Medical Imaging, Inc., Q3 2014 Earnings Call, Nov 12, 2014

Lantheus Medical Imaging, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Announces Asset Write-Off for the Second Quarter Ended June 30, 2014

Lantheus Medical Imaging, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company announced total revenues of $75,613,000 compared to $70,601,000 for the same period a year ago. Operating income was $9,980,000 compared to loss of $3,876,000 for the same period a year ago. Loss before income taxes was $762,000 compared to $14,582,000 for the same period a year ago. Net loss was $1,636,000 compared to $14,500,000 for the same period a year ago. Net cash flows used in operating activities was $4,225,000 compared to $15,963,000 for the same period a year ago. Capital expenditures were $1,998,000 compared to $1,347,000 for the same period a year ago. EBITDA was $14,235,000 compared to $2,734,000 for the same period a year ago. Adjusted EBITDA was $16,317,000 compared to $6,545,000 for the same period a year ago. For the six months, the company announced total revenues of $148,949,000 compared to $141,619,000 for the same period a year ago. Operating income was $18,469,000 compared to loss of $13,112,000 for the same period a year ago. Loss before income taxes was $3,239,000 compared to $33,766,000 for the same period a year ago. Net loss was $2,921,000 compared to $34,312,000 for the same period a year ago. Net cash flows used in operating activities was $4,240,000 compared to $16,113,000 for the same period a year ago. Capital expenditures were $3,480,000 compared to $2,796,000 for the same period a year ago. EBITDA was $348,000 compared to $31,838,000 for the same period a year ago. Adjusted EBITDA was $21,918,000 compared to $39,879,000 for the same period a year ago. For the second quarter, the company announced asset write-off of $91,000 compared to $958,000 for the same period a year ago.

Similar Private Companies By Industry

Company Name Region
Stiefel Laboratories, Inc. United States
CardioPharma, Inc. United States
Trace Genetics, Inc. United States
PharmStar, Inc. United States
Lewis & Clark Pharmaceuticals Subsidiary, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Lantheus Medical Imaging, Inc., please visit www.lantheus.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.